Heyman Richard A. sold $41K of ORIC (indirect holdings)
Heyman Richard A. sold 3,200 indirectly-held shares of Oric Pharmaceuticals, Inc. (ORIC) at $12.91 on 2026-10-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The transaction is small and pre‑arranged, suggesting limited new information for traders.
Market read
A routine insider sale with modest size; unlikely to move the stock significantly.
What to watch
Potential upcoming clinical data releases could outweigh the modest insider sell.
Background
Form 4 filings disclose insider transactions; this filing reports a director's sale under a 10b5‑1 plan.
Ticker impact
Director Richard Heyman sold 3,200 shares for $41,325 via a 10b5-1 plan, reducing his stake.
likely slight pressure as the market prices in the insider sell
The sale is small ($41k) and executed under a pre‑arranged plan, limiting informational value but may cause minor short‑term downside.
Market effects
Minimal impact on the biotech sector; typical insider sales are routine.
No broader regional effect.
Limited to ORIC shareholders.
Counterpoint
The sale could be purely liquidity‑driven and not indicative of company fundamentals.
Key entities
- CompanyOric Pharmaceuticals, Inc.
Biotech firm listed on NASDAQ under ticker ORIC.
- PersonRichard A. Heyman
Director of Oric Pharmaceuticals.
